Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

Bristol-Myers Squibb has teamed up with BioNTech to co-develop a bispecific antibody, BNT327, targeting multiple solid tumors ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

German-based BioNTech , best known for its collaboration with Pfizer during the COVID-19 pandemic for developing vaccines, ...

This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and ...

In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...

BioNTech (NasdaqGS:BNTX) has seen a significant price movement in the past week, with its stock rising by 15%, compared to a 2% increase in the broader market. The recent co-development and ...

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...